Cognito Therapeutics
Developing a novel therapeutic approach for Alzheimer's disease.
About
Cognito Therapeutics is a clinical-stage biopharmaceutical company focused on developing a novel therapeutic approach for Alzheimer's disease. Their lead product candidate, Spectris™, is a non-invasive, wearable neurostimulation device designed to treat cognitive decline associated with Alzheimer's. The company aims to address the underlying pathology of the disease by modulating brain activity. Teams look it up for Biotechnology, Medical Devices, Neuroscience.
Frequently asked
What does Cognito Therapeutics do?
Cognito Therapeutics is a Biotechnology company that offers Hardware. Teams look it up for Medical Devices, Neuroscience, Healthcare. It is based in Boston, Massachusetts, USA and was founded in 2011. Public records show $213M in total funding. Compare it on funding, headcount, reviews and nearby alternatives rather than the marketing line alone.
How much funding has Cognito Therapeutics raised?
Cognito Therapeutics has raised a total of $213M in funding. The most recent round on record is Series C.
Where is Cognito Therapeutics headquartered?
Cognito Therapeutics is headquartered in Boston, Massachusetts, USA.
When was Cognito Therapeutics founded?
Cognito Therapeutics was founded in 2011.
What industry does Cognito Therapeutics operate in?
Cognito Therapeutics operates in Biotechnology, Medical Devices, Neuroscience, Healthcare.
Strength of the site’s backlink profile, on Ahrefs’ 0-100 Domain Rating scale. Licensed third-party data, not our opinion.
How well an AI agent can read and use this site: structured data, clean markup, and whether key facts are reachable without running JavaScript. We scan the live site.
Google PageSpeed mobile performance for the company’s own site. Measured by Google, not by us.